Drugs / MB02-SP
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04408989 | Jan → Aug 2021 | — | mAbxience Research S.L. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MB02-SP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04408989 ↗ |
| Known as | MB02-SP (Bevacizumab Biosimilar) | “MB02-SP (Bevacizumab Biosimilar)” NCT04408989 ↗ |
| Route | Intravenous | “Solution for intravenous infusion, single dose of 1mg/kg, administered as 90-minute infusion” NCT04408989 ↗ |